C. difficile Infection

Infection caused by the bacterium C. difficile is a major healthcare threat in hospitals, long-term care homes, and increasingly in the wider community.

We are developing ridinilazole (SMT19969), a highly selective antibiotic that has the potential to treat CDI and reduce disease recurrence, the key clinical issue.


Gonorrhoea has been identified as one of three urgent threats by the US Centers for Disease Control and Prevention (‘CDC’) and a high priority pathogen by the World Health Organisation.

Our research programme is developing new mechanism antibiotics to treat all gonorrhoea.

C. Difficile Infections banner image

Discuva Platform

The world is entering an era of untreatable infections. Without urgent action, once easily curable infections could become global health crises.

Summit approach to tackling this problem is to use its Discuva Platform to develop new mechanism antibiotics.


We regularly publish data on our drug programmes in peer-reviewed journals and gives presentations at leading international conferences. This section provides access to this information.